Background Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) with 3 h incubation is recommended
Introduction
The concept of fractional laser as enhancement technique to overcome skin barrier and to assist topical drug delivery has recently been used in clinical protocols. 1 Pretreatment with ablative CO 2 fractional laser (AFXL) removes stratum corneum in fractions, and partitions occur between drug and epidermis or dermis providing direct delivery and better distribution of hydrophilic drugs. 2, 3 These microscopic laser channels bring the drug in closer proximity to the dermis, and a higher concentration of the drug is achieved at target location in deeper skin layers. 1, 4 The most frequently evaluated drugs in the field of AFXLassisted drug delivery according to preclinical and clinical studies are photosensitizers, especially methyl aminolevulinate (MAL) for photodynamic therapy (PDT). 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] PDT can be used as field therapy for actinic keratoses (AKs), when lesions become multiple, less well defined and more confluent in nature. This manifestation is seen on a chronically photodamaged area with subclinical, early and late AKs, giving rise to the concept of field cancerization. The goals of field treatment were to eliminate not only clinically visible but also subclinical lesions and to prevent progression to invasive SCC. [14] [15] [16] [17] Photodynamic therapy effectiveness depends on MAL conversion to photoactive fluorescent protoporphyrin IX (PpIX) in dysplastic cells. When MAL is activated by light, it triggers a photochemical reaction by which reactive oxygen species (ROS) are produced and selectively kill tumour cells. 18, 19 An AFXL pretreatment can increase PDT efficacy by providing an alternative pathway for topical MAL delivery that accelerates the penetration of photosensitizer and accumulation of PpIX. 3, [5] [6] [7] 20, 21 This option could be used to shorten the approved 3-h MAL incubation time, which is obviously advantageous for both patients and physicians. 22 Our aim was to evaluate a more rapid preventing procedure combining PDT with AFXL pretreatment. The objectives of the current intraindividual right-left study were to compare the preventive effect in the development of new non-melanocytic skin cancers (NMSCs) of AFXL-assisted MAL-PDT with 1-h incubation with that of conventional PDT (CPDT) in patients with clinical and histological signs of field cancerization.
Materials and methods

Patients
The study was conducted between September 2015 and December 2016 in the First Dermatologic Department of Aristotle University of Thessaloniki, Greece. Eligibility criteria were age over 18 years, histologically confirmed the presence of abnormal architecture and satellite atypical keratinocytes in the epidermis, indicative of early in situ SCC of AK type, in clinically normal tissue samples of photodamaged skin adjacent to NMSCs (histology of these pre-existing lesions was mandatory for BCCs and SCCs, whereas clinical diagnosis was sufficient for AKs), symmetrical distribution of the lesions over two mirror photodamaged areas of up to 50 cm 2 over the face or scalp, personal history of previous NMSCs over these regions. Exclusion criteria included pregnancy or lactation, photosensitivity, known allergy to the components of MAL cream, immunosuppression, active infectious disease, topical treatment in the field area within the past 8 weeks, patients with Fitzpatrick type IV-VI, isotretinoin use within the previous 6 months and history of keloid formation or hypertrophic scarring. The study was conducted in accordance with the Declaration of Helsinki. Institutional ethical committee approved the protocol; patients provided signed informed concept for their participation.
Study design and protocol
At baseline, patient demographic data were recorded and clinical evaluation of patients' face and scalp was performed. Two distinct contralateral areas of face or scalp up to 50 cm 2 with multiple AKs were selected. Diagnosis of AKs was set on clinical and dermoscopical basis. Both fields were digitally photographed, whereas AKs were counted and mapped on anatomical diagrams. Treatment areas were then randomized to receive either CPDT or AFXL-assisted PDT. Selected areas were randomly allocated, using a computer-generated random allocation scheme. Both treatment fields were pretreated with curettage. There was no use of topical anaesthesia over treated areas. A session of ultra-pulse fractional CO 2 laser (Spectra-SP, MAX Engineering Ltd, South Korea) using scanner handpiece was performed on the entire AFXL-assisted field. Laser parameters were wavelength of 10 600 nm, char-free operation mode, power 30 W, pulse width 100 l/s, repetition rate 100 Hz, spot density 11 9 11 (121 spots/cm 2 ) and beam size of 120 lm. Immediately thereafter, MAL cream (Metvix, Lab. Galaderma, Alby Sur Cheran, France) was applied in 1 mm thickness over both treatment areas and was left under occlusion for only 1 h in AFXL-assisted PDT area and for 3 h in the CPDT area. After incubation period, occlusive dressing and cream remnants were removed and treatment areas were illuminated with red light-emitting diode (LED) lamps (Aktilite CL 128; Galderma) with peak irradiance at 630 nm and a total light dose of 37 J/cm 2 . All patients received two sessions of CPDT and AFXL-assisted PDT 1 week apart.
Patients were evaluated 3, 6, 9 and 12 months after treatment. Primary outcome measure was the number of new AKs in each treatment area. Clinical assessment was performed by the same blinded investigator who had no access to documents related to treatment procedure. Treatment areas were identified by baseline digital photography which also served as a map for initial lesions and for identifying new lesions. Baseline AKs were not recorded even if they were not completely resolved. Only new clinically present lesions were counted and recorded on anatomical diagrams.
Secondary outcome measures included adverse events during treatment and follow-up period.
Statistics
Statistical analysis was performed using two-sided Wilcoxon paired samples test. Significance level was P < 0.05. Mean time to occurrence of lesions was assessed with 95% confidence intervals (CIs).
Results
Evaluation of new lesions
Fifty patients were enrolled in the study. All patients had severe photodamaged skin and a positive history of at least one NMSC including BCCs (23/50), SCCs (9/50) and AKs (50/50). Overall 42 (28 male, 14 female) patients completed the study. Eight patients were lost in follow-up and were not included in the final analysis. The age range was between 56 and 80 years (mean: 68 years, SD: AE7.1). Selected areas were located on the face in 22 patients and on the scalp in 20 patients. Patient skin type included Fitzpatrick type 1 (3/42), type 2 (13/42) and type 3 (26/42). Patient demographic characteristics are summarized in Table 1 .
Total number of new lesions, occurring during the intervals from baseline until each time point of follow-up, were statistically analysed. There was no statistically significant difference regarding the numbers of new lesions between the two treatment fields at any time of follow-up.
Data were further analysed with respect to the number of new lesions occurring at the first, second, third and fourth trimester of the follow-up period (baseline -month 3, month 3-6, month 6-9 and month 9-12). There were no statistically significant differences between treatment areas with P and z values being P = 0.317, z = À1.000 for the first, P = 0.655, z = À0.447 for the second, P = 0.655, z = À0.477 for the third and P = 0.157, z = À1.414 for the fourth trimester, respectively. Of note is the steep increase in number of new lesions over both fields after the second trimester which continued till the 12-month follow-up.
Furthermore, the mean time of occurrence of new lesions was 9.55 AE 3.02 months (95% CI: 8.63-10.49) for AFXL-PDT and 9.68 AE 2.84 months (95% CI: 8.77-10.58) for CPDT. Again, there was no statistically significant difference. At the 3-month follow-up, 90.5% (38/42) of the patients were free of new lesions on the AFXL-PDT field, percentage that gradually reduced to 48% (20/42) at the 12-month follow-up. The number of patients free of new lesions on the CPDT field was reduced from 93% (39/ 42) at 3 months to 52% (22/42) at 12 months. Total number of new lesions and patients free of new lesions over both treatment areas at each time point of follow-up are presented in Table 2 .
Safety
No severe adverse events were recorded during treatment and follow-up period. All patients completed treatment as scheduled.
No patient reported pain during AFXL laser procedure. On the contrary, all patients reported burning sensation and pain during PDT illumination (42/42, 100%). Local phototoxic reactions that resolved within 5-7 days were observed over both sides and included erythema, oedema, pustular eruption and crusting formation. Table 3 presents local phototoxic reactions and their severity over both fields. Clinical evaluation for long-term skin reactions at follow-up visits showed no scarring and no pigmentary changes (hyperpigmentation or hypopigmentation) in both treated areas.
Discussion
Photodynamic therapy is a noninvasive treatment option for NMSC with high efficacy and capable of field treatment, providing optimum cosmetic outcomes. Treatment-related downtime is, however, prolonged as a 3-h occlusion is necessary. This factor makes the procedure inconvenient for both patients and physicians.
Different types of physical drug enhancement techniques were proposed in the literature. Laser-assisted drug delivery was first described in 1987 and initially practiced with fully ablative laser. 23 In 2004, fractional photothermolysis was developed, using focused laser beams to create arrays of microscopic injuries, while leaving intermediated skin intact. 24 The most commonly used AFXL systems include erbium-doped yttriumaluminium-garnet (Er: YAG laser -AFXL; k = 2940 nm) and CO 2 (CO 2 -AFXL; k = 10 600 nm) laser. [1] [2] [3] 25, 26 Studies combining PDT with AFXL pretreatment demonstrated improved PDT efficacy. The first evidence of AFXL-PDT superiority compared with that of CPDT in the treatment of AK in field-cancerized skin was presented by Togsverd-Bo et al. 8 AFXL-PDT and CPDT were performed on scalp or face as field directed treatments with MAL incubation for 3 h and photoexcitation with red LED light. AFXL-PDT was not only more effective in the treatment of AKs but also in the prevention of occurrence of new lesions.
Helsing et al. compared the efficacy of AFXL-PDT performed with CO 2 laser vs. AFXL alone for difficult-to-treat AKs in organ-transplant patients. Complete response of AKs was significantly higher for AFXL-PDT (73%) compared with AFXL alone Laser-assisted vs. cPDT for NMSC prevention (31%). Moreover, AFXL-PDT was more effective in reducing the grade of AKs.
10
Another trial evaluated the efficacy of AFXL-PDT vs. CPDT in treating 271 facial AKs of 45 Korean patients. AFXL-PDT using Er: YAG laser was significantly more effective than CPDT at treating AKs of all grades. The efficacy of AXFL-PDT was most pronounced in moderate-to-thick lesions. AFXL-PDT also showed a lower lesion recurrence rate than MAL-PDT (9.7% vs. 26.6%).
11 Togsverd-Bo et al. compared AFXL with Er:YAG laser-assisted daylight photodynamic therapy (AFXL-DLPDT) with DLPDT, CPDT and AFXL alone in field treatment of AKs in organ-transplant recipients. Sixteen patients with a total of 542 AK were treated in four symmetric areas. Three months later, complete response rates were 74% for AFXL-DLPDT, 46% for DLPDT, 50% for CPDT and 5% for AFXL. 12 However, few studies have examined the efficacy of PDT after AFXL application with a photosensitizer incubation period shorter than 3 h. Jang YH et al. 9 demonstrated that AFXL-PDT is effective after reduction in MAL incubation period to 70 min. The same team concluded that the use of AFXL before PDT reduced MAL incubation time to 90 min achieving similar treatment efficacy with CPDT. 22 In a randomized trial, Choi et al. compared the efficacy, recurrence rate, cosmetic outcome and safety between AFXL-PDT with 2 and 3 h of incubation with that of CPDT for the treatment of facial and scalp AKs. Three months after treatment, 3-h AFXL-PDT was significantly more effective, achieving also significantly lower recurrence rates. 13 In 2017, a randomized controlled trial by Alexiades et al. assessed the efficacy of short incubation aminolevulinic acid (ALA) followed by blue light PDT with and without previous fractional CO 2 application for the treatment of facial AKs. The author demonstrated that ultrashort 15-and 30-min incubation ALA PDTs are of limited efficacy for the treatment of AKs. Pretreatment with fractional C02 augmented significantly ALA-PDT efficacy for AK clearance at previous ultrashort ALA incubations. 27 Another interesting point is whether daylight PDT combined with AFXL could result in the same preventive effect. Although this was not studied in our trial, taking into account that daylight PDT has proved efficacy in the same clinical scenario (prevention of new AK in cancerized fields), we expect that this would not change with the combination. On the other hand, we should underline that incubation time is not a limitation of daylight PDT. 28 To the best of our knowledge, this is the first study to evaluate the efficacy of AFXL-PDT with a short incubation time as a preventive treatment in the development of new AKs and compare it with that of CPDT with a 3-h incubation time in immunocompetent patients suffering from clinically and histologically proven actinic field damage. CPDT has shown efficacy in the treatment of both clinically evident and subclinical lesions. 16, 17 A randomized, placebo-controlled study, conducted in our department confirmed that CPDT delays the occurrence of new AKs in immunocompetent patients. 16 One of the main CPDT limitations is, however, the prolonged incubation period of the photosensitizer before illumination. Our clinical trial demonstrated that AFXL-PDT can be performed with a shorter incubation time (1 h) along with a preventive efficacy similar to that of CPDT. Based on our results, there was no statistically significant difference in the number of new AKs at any time point of follow-up between the two treatment areas. Furthermore, there was no statistically significant difference in terms of mean time of development of new AKs between contralateral fields. With respect to safety, both modalities were safe and well tolerated. Limitations of our study include small sample size and lack of a placebo arm.
In conclusion, our results demonstrate that AFXL-PDT with 1-h incubation and CPDT are equally effective with respect to their preventive potential against new AKs formation in patients with field changes. Better knowledge of molecular mechanisms implicated in AFXL-assisted MAL delivery and calibration of laser settings will lead us to optimize MAL delivery rate and biodistribution. Pretreatment with AFXL seems to be a good strategy to reduce photosensitizer occlusion time and to overcome the long treatment downtime related to CPDT. Additional studies are needed to optimize treatment protocols.
